Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
484.24
+3.91 (0.81%)
At close: Feb 21, 2025, 4:00 PM
489.00
+4.76 (0.98%)
After-hours: Feb 21, 2025, 4:47 PM EST
Vertex Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 11,020 | 9,869 | 8,931 | 7,573 | 6,203 | Upgrade
|
| Other Revenue | - | - | - | 1 | 2.9 | Upgrade
|
| Revenue | 11,020 | 9,869 | 8,931 | 7,574 | 6,206 | Upgrade
|
| Revenue Growth (YoY) | 11.66% | 10.51% | 17.91% | 22.06% | 49.08% | Upgrade
|
| Cost of Revenue | 1,531 | 1,262 | 1,080 | 2,842 | 2,381 | Upgrade
|
| Gross Profit | 9,490 | 8,607 | 7,850 | 4,732 | 3,825 | Upgrade
|
| Selling, General & Admin | 1,432 | 1,137 | 944.7 | 840.1 | 770.5 | Upgrade
|
| Research & Development | 3,465 | 3,163 | 2,527 | - | - | Upgrade
|
| Operating Expenses | 4,897 | 4,300 | 3,472 | 840.1 | 770.5 | Upgrade
|
| Operating Income | 4,593 | 4,308 | 4,378 | 3,892 | 3,054 | Upgrade
|
| Interest Expense | -30.6 | -44.1 | -54.8 | -61.5 | -58.2 | Upgrade
|
| Interest & Investment Income | 598.1 | 614.7 | 144.6 | 4.9 | 22.2 | Upgrade
|
| Currency Exchange Gain (Loss) | -27.3 | -24.6 | -15.1 | -13.9 | -16.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -49.3 | 9.3 | -0.6 | 1.7 | 0.8 | Upgrade
|
| EBT Excluding Unusual Items | 5,084 | 4,863 | 4,453 | 3,824 | 3,003 | Upgrade
|
| Merger & Restructuring Charges | -197.6 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -9.5 | -7.5 | -149.1 | 17.1 | 311.9 | Upgrade
|
| Asset Writedown | - | - | -13 | - | - | Upgrade
|
| Other Unusual Items | 0.5 | 51.6 | 57.5 | 3.1 | -13.1 | Upgrade
|
| Pretax Income | 248.5 | 4,380 | 4,232 | 2,730 | 3,117 | Upgrade
|
| Income Tax Expense | 784.1 | 760.2 | 910.4 | 388.3 | 405.2 | Upgrade
|
| Earnings From Continuing Operations | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade
|
| Net Income to Company | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade
|
| Net Income | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade
|
| Net Income to Common | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade
|
| Net Income Growth | - | 8.96% | 41.84% | -13.63% | 130.43% | Upgrade
|
| Shares Outstanding (Basic) | 258 | 258 | 256 | 258 | 260 | Upgrade
|
| Shares Outstanding (Diluted) | 258 | 261 | 259 | 260 | 263 | Upgrade
|
| Shares Change (YoY) | -1.00% | 0.54% | -0.31% | -1.33% | 1.04% | Upgrade
|
| EPS (Basic) | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | Upgrade
|
| EPS (Diluted) | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | Upgrade
|
| EPS Growth | - | 8.35% | 42.29% | -12.44% | 128.16% | Upgrade
|
| Free Cash Flow | -790.3 | 3,337 | 3,925 | 2,409 | 2,994 | Upgrade
|
| Free Cash Flow Per Share | -3.06 | 12.81 | 15.15 | 9.27 | 11.37 | Upgrade
|
| Gross Margin | 86.11% | 87.21% | 87.90% | 62.48% | 61.63% | Upgrade
|
| Operating Margin | 41.67% | 43.65% | 49.03% | 51.39% | 49.21% | Upgrade
|
| Profit Margin | -4.86% | 36.68% | 37.20% | 30.92% | 43.70% | Upgrade
|
| Free Cash Flow Margin | -7.17% | 33.81% | 43.95% | 31.80% | 48.24% | Upgrade
|
| EBITDA | 4,775 | 4,477 | 4,527 | 4,018 | 3,164 | Upgrade
|
| EBITDA Margin | 43.33% | 45.36% | 50.69% | 53.05% | 50.98% | Upgrade
|
| D&A For EBITDA | 182 | 169.5 | 148.3 | 125.6 | 109.5 | Upgrade
|
| EBIT | 4,593 | 4,308 | 4,378 | 3,892 | 3,054 | Upgrade
|
| EBIT Margin | 41.67% | 43.65% | 49.03% | 51.39% | 49.21% | Upgrade
|
| Effective Tax Rate | 315.53% | 17.36% | 21.51% | 14.22% | 13.00% | Upgrade
|
| Revenue as Reported | - | - | - | 7,574 | 6,206 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.